US 11,807,693 B2
Apelin polypeptides
Jerry Ryan Holder, Simi Valley, CA (US); Gayathri Swaminath, Brisbane, CA (US); Michael J. Frohn, Thousand Oaks, CA (US); Brian Alan Lanman, Woodland Hills, WA (US); Anthony B. Reed, Newbury Park, CA (US); Leslie P. Miranda, Thousand Oaks, CA (US); John Gordon Allen, Newbury Park, CA (US); Alexander J. Pickrell, Westlake Village, CA (US); Aaron C. Siegmund, Ventura, CA (US); Lewis D. Pennington, Arlington, MA (US); and Bryant Yang, Agoura Hills, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Jan. 28, 2021, as Appl. No. 17/160,819.
Application 17/160,819 is a division of application No. 15/317,911, granted, now 10,941,182, previously published as PCT/US2015/035205, filed on Jun. 10, 2015.
Claims priority of provisional application 62/010,322, filed on Jun. 10, 2014.
Prior Publication US 2021/0261619 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/08 (2006.01); C07K 14/47 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 38/10 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 38/10 (2013.01); A61K 47/542 (2017.08); A61K 47/60 (2017.08); C07K 14/47 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 6 Claims
 
1. A method for treating heart failure in a subject in need thereof comprising administering to the subject an isolated polypeptide comprising the amino acid sequence SEQ ID NO: 16; and wherein the polypeptide is conjugated to polyethelyene glycol by 3-mercaptopropanoic acid.